Figure 5D shows the results involving CRS and BDNF-shRNA. The usage of BDNF-shRNA evidently prevented the decreasing effects of oroxylin A on the FST immobility [ANOVA: F (6, 77) = 29.071, p < 0.01] and TST immobility [ANOVA: F (6, 77) = 26.547, p < 0.01] of mice subjected to CRS (n = 12, p < 0.01). Moreover, the usage of BDNF-shRNA evidently prevented the enhancing effects of oroxylin A on the sucrose preference of mice subjected to CRS [ANOVA: F (6, 77) = 17.662, p < 0.01] (n = 12, p < 0.01). This evidence concerns the gene BDNF and congenital rubella syndrome.